• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: FDA to tackle drug compounding policy

September 18, 2017 By Sarah Faulkner

FDAFDA commissioner Scott Gottlieb wants to encourage compounding pharmacies to register under a law that brings such businesses under the authority of the FDA rather than state pharmacy boards, according to new reports from Reuters.

Pharmacies that specialize in compounding services make custom medications by combining, or compounding, FDA-approved drugs in strengths personalized to an individual patient.

After a meningitis outbreak linked to a now-defunct compounder, the New England Compounding Center, turned deadly in 2012, Congress passed the Drug Quality and Security Act. The law established that compounding pharmacies could register with the FDA and be allowed to sell products to hospitals and physician practices without prescriptions for individual patients.

In registering with the FDA, the pharmacies are required to follow federal manufacturing standards and be available for routine inspections.

Around 70 companies have registered under such a category, called “outsourcing facilities”, according to Reuters.

If a compounder decided not to register with the FDA, it remains under state authority and is restricted to selling compound drugs for specific patients with a prescription.

In an effort to encourage more compounding pharmacies to register, the FDA is slated to release draft guidance in the next two months, Gottlieb said. The guidance will establish the regulatory agency’s intention to recalibrate its enforcement priorities based on the size of the compounder and the risk associated with its product.

“We’re looking at ways we can provide more of a gradation in our regulatory architecture so we don’t have a one-size-fits-all approach,” Gottlieb told the newswire.

Groups like the American Pharmacists Association have criticized the FDA in the past, arguing that the federal group was overstepping its bounds by regulating state-licensed pharmacies.

Gottlieb said he stands by the FDA and that he expects no slowdown in terms of its enforcement of the 2013 law. New guidance, he said, will address the concerns voiced by smaller pharmacies that are worried about the expense of regulatory compliance.

The upcoming draft guidance will establish less burdensome regulatory requirements for smaller firms compared with larger outsourcing facilities.

“I want to move more of them into a compliant space, and I‘m willing to work with compounders and the broader community to find some regulatory accommodation that gets more of them into a compliant space,” he told Reuters.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS